Chemomab Therapeutics (CMMB) Competitors $3.09 +0.04 (+1.31%) Closing price 09/5/2025 04:00 PM EasternExtended Trading$3.09 0.00 (0.00%) As of 09/5/2025 06:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock CMMB vs. PDSB, KPTI, ICCC, DTIL, ALXO, VTVT, CLNN, ATNM, IMA, and JMACShould you be buying Chemomab Therapeutics stock or one of its competitors? The main competitors of Chemomab Therapeutics include PDS Biotechnology (PDSB), Karyopharm Therapeutics (KPTI), ImmuCell (ICCC), Precision BioSciences (DTIL), ALX Oncology (ALXO), vTv Therapeutics (VTVT), Clene (CLNN), Actinium Pharmaceuticals (ATNM), ImageneBio (IMA), and Maxpro Capital Acquisition (JMAC). These companies are all part of the "pharmaceutical products" industry. Chemomab Therapeutics vs. Its Competitors PDS Biotechnology Karyopharm Therapeutics ImmuCell Precision BioSciences ALX Oncology vTv Therapeutics Clene Actinium Pharmaceuticals ImageneBio Maxpro Capital Acquisition PDS Biotechnology (NASDAQ:PDSB) and Chemomab Therapeutics (NASDAQ:CMMB) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, media sentiment, institutional ownership, profitability, earnings, analyst recommendations, valuation and risk. Does the media refer more to PDSB or CMMB? In the previous week, PDS Biotechnology and PDS Biotechnology both had 2 articles in the media. Chemomab Therapeutics' average media sentiment score of 0.99 beat PDS Biotechnology's score of 0.88 indicating that Chemomab Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment PDS Biotechnology 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Chemomab Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts recommend PDSB or CMMB? PDS Biotechnology currently has a consensus target price of $10.00, suggesting a potential upside of 733.33%. Chemomab Therapeutics has a consensus target price of $26.50, suggesting a potential upside of 757.61%. Given Chemomab Therapeutics' higher possible upside, analysts clearly believe Chemomab Therapeutics is more favorable than PDS Biotechnology.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score PDS Biotechnology 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00Chemomab Therapeutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has higher valuation and earnings, PDSB or CMMB? Chemomab Therapeutics is trading at a lower price-to-earnings ratio than PDS Biotechnology, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPDS BiotechnologyN/AN/A-$37.61M-$0.92-1.30Chemomab TherapeuticsN/AN/A-$13.94M-$2.36-1.31 Is PDSB or CMMB more profitable? Chemomab Therapeutics' return on equity of -94.71% beat PDS Biotechnology's return on equity.Company Net Margins Return on Equity Return on Assets PDS BiotechnologyN/A -184.56% -79.00% Chemomab Therapeutics N/A -94.71%-76.53% Which has more risk and volatility, PDSB or CMMB? PDS Biotechnology has a beta of 1.15, indicating that its stock price is 15% more volatile than the S&P 500. Comparatively, Chemomab Therapeutics has a beta of 0.51, indicating that its stock price is 49% less volatile than the S&P 500. Do insiders and institutionals have more ownership in PDSB or CMMB? 26.8% of PDS Biotechnology shares are owned by institutional investors. Comparatively, 46.1% of Chemomab Therapeutics shares are owned by institutional investors. 9.2% of PDS Biotechnology shares are owned by insiders. Comparatively, 11.9% of Chemomab Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. SummaryChemomab Therapeutics beats PDS Biotechnology on 7 of the 10 factors compared between the two stocks. Get Chemomab Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CMMB and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CMMB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CMMB vs. The Competition Export to ExcelMetricChemomab TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$14.57M$3.18B$5.83B$9.93BDividend YieldN/A2.27%6.70%4.52%P/E Ratio-1.3121.1076.1526.11Price / SalesN/A466.44562.61123.62Price / CashN/A45.7236.9959.28Price / Book1.089.8711.486.09Net Income-$13.94M-$53.42M$3.29B$266.51M7 Day Performance-1.59%2.93%1.27%0.46%1 Month Performance-21.17%9.85%7.94%4.59%1 Year Performance-59.13%15.74%62.94%26.04% Chemomab Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CMMBChemomab Therapeutics3.4319 of 5 stars$3.09+1.3%$26.50+757.6%-66.3%$14.57MN/A-1.3120News CoverageShort Interest ↓PDSBPDS Biotechnology2.5148 of 5 stars$1.26+1.2%$10.00+696.8%-60.0%$58.52MN/A-1.3620KPTIKaryopharm Therapeutics3.9004 of 5 stars$6.75-5.1%$34.00+404.1%-44.8%$58.48M$145.24M-0.46380News CoverageICCCImmuCell0.5771 of 5 stars$6.41+0.2%N/A+63.1%$58.01M$26.49M33.7470Gap UpDTILPrecision BioSciences3.7406 of 5 stars$4.76-2.9%$47.00+887.4%-47.9%$56.12M$68.70M-0.54200Positive NewsALXOALX Oncology3.9913 of 5 stars$1.04-11.5%$3.30+218.8%-38.7%$55.42MN/A-0.4740News CoveragePositive NewsShort Interest ↓Gap DownVTVTvTv Therapeutics1.3105 of 5 stars$17.21+6.0%$35.50+106.3%+20.7%$54.90M$1.02M-5.529Positive NewsGap UpCLNNClene3.7298 of 5 stars$5.37+1.0%$33.00+514.3%-4.4%$54.05M$340K-1.44100News CoverageATNMActinium Pharmaceuticals1.7433 of 5 stars$1.72-3.7%$4.50+162.4%-8.1%$53.50MN/A-1.2330Short Interest ↑IMAImageneBio2.8223 of 5 stars$13.28-0.9%$35.50+167.3%-60.0%$53.39M$9.16M-1.7370News CoverageJMACMaxpro Capital AcquisitionN/A$3.93-6.1%N/A+4,512.8%$52.80MN/A0.002,021 Related Companies and Tools Related Companies PDSB Competitors KPTI Competitors ICCC Competitors DTIL Competitors ALXO Competitors VTVT Competitors CLNN Competitors ATNM Competitors IMA Competitors JMAC Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CMMB) was last updated on 9/6/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredScientists Discover Untapped Energy Source in Heart of USACrash Coming Sept 30? Analysts Warn of New Crisis A new problem on the U.S. power grid is putting millions ...Altimetry | Sponsored6-Figure Target for BTC by 2025The U.S. just announced it's putting GDP data directly onto Bitcoin and Ethereum blockchains. Could this spa...Crypto 101 Media | SponsoredWhat Steve Bannon revealed about Trump’s gold playA Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...Reagan Gold Group | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredAlert: Prepare for Trump's Dollar OverhaulPresident Trump just signed a game-changing law… That could soon upgrade the U.S. dollar in your checking a...Brownstone Research | SponsoredHamilton’s 100-to-1 tradePorter Stansberry has made a career out of bold calls that go against the mainstream narrative — from the 1998...Porter & Company | SponsoredTrump's 2025 Economic Revolution Is Here Are Your Retirement Savings Ready?Time is short. Trump's reforms may be coming fast—and the financial system roller coaster may be a ride that y...Goldco Precious Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Chemomab Therapeutics Ltd. Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Chemomab Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CMMB Stock Alerts